Join Growin Stock Community!

Cencora inc(COR.US AI Earnings Summary)

US StockHealthcare
No presentation for COR

COR AI Earnings Summary (In-Depth)

Last updated: 2026-11-04 (US time)

2026 Q4 (Fiscal Year)

Core Highlights

  • Stock Price Reaction: CENCORA INC announced its earnings on November 4, 2026. Benefiting from strong demand for specialty pharmaceuticals and M&A synergies, adjusted EPS and revenue performance were impressive. The stock closed at $354.00 on 11/4, up 3.96% from the 11/3 close of $340.50.
  • Market Expectations: No market expectations comparison data available; no magnitude determination or cause analysis performed.
  • Performance vs. Previous Guidance: All targets met or exceeded. Full-year adjusted diluted EPS of $17.97 was approximately 0.1% above the upper bound of guidance. Full-year adjusted operating income growth of 14% fell near the upper bound of the guidance range. Adjusted free cash flow of approximately $3.8B was higher than guidance.
  • In a Nutshell: COR leveraged strong demand for specialty drugs and the OneOncology acquisition to exceed all full-year profit and cash flow guidance, with the market responding as the stock closed up 3.96% at $354.00 on 11/4.

Quarterly Highlights

Record full-year and quarterly results as OneOncology acquisition benefits fully materialize, driving a 22% YoY increase in adjusted operating income this quarter.

  1. Full-year adjusted diluted EPS reached $17.97, exceeding the upper bound of internal expectations: Fiscal year 2026 full-year adjusted diluted EPS was $17.97, up 12% YoY, higher than the $17.95 upper limit of the guidance provided last quarter. Full-year adjusted operating income grew 14%, landing near the upper end of the internal expectation range, a record high for several consecutive years.

  2. Quarterly adjusted diluted EPS up 21% YoY to $4.66, the strongest quarter of the year: Fiscal year 2026 fourth quarter (hereafter referred to as "this quarter") adjusted diluted EPS reached $4.66, up 21% YoY, benefiting from OneOncology's contribution, continued growth in specialty drug volume, and an easier expense comparison base. This quarter was also the fastest-growing quarter for adjusted operating income among the four quarters of the year.

  3. U.S. Healthcare Solutions segment operating income up 22% YoY, the strongest quarter of the fiscal year: This quarter, the U.S. Healthcare Solutions segment's adjusted operating income reached $998M, up 22% YoY. The operating margin expanded from 1.10% in the same period last year to 1.27%. Growth momentum came from specialty drug sales to health systems and physician practices, OneOncology contributions, and an easier expense comparison base.

  4. GLP-1 drugs (diabetes and weight management) up $2.8B YoY, becoming a key growth engine for the U.S. segment: In this quarter, U.S. segment sales of GLP-1 drugs increased by $2.8B compared to the same period last year. Simultaneously, manufacturer price reductions (WAC decreases) created a $2.8B revenue headwind, largely offsetting the sales gain. However, GLP-1 volume growth remains positive for the overall profit structure.

  5. Adjusted gross margin expanded 57 bps QoQ to 4.04%, with OneOncology as the primary driver: Consolidated adjusted gross profit this quarter reached $3.6B, up 23% YoY. Gross margin increased by 57 basis points YoY to 4.04%, primarily due to the high-margin specialty business brought in by the OneOncology acquisition completed in February 2026. Excluding OneOncology and Retina Consultants of America (RCA), operating expense growth was below 3%, demonstrating solid core expense control.

  6. International Healthcare Solutions segment constant currency operating income up 19% YoY, with strong performance in Canada and Global Specialty Logistics: International segment revenue was $7.8B, up 5% YoY (approx. 8% at constant currency). Adjusted operating income was $152M, up 16% YoY (19% at constant currency). CFO Eva Boratto noted that the Canadian business performed exceptionally well driven by high program win rates, while Global Specialty Logistics and Third-Party Logistics (3PL) businesses maintained double-digit operating income growth.

  7. Full-year adjusted free cash flow reached $3.8B, significantly exceeding the internal expectation of approx. $3.0B: Fiscal year 2026 full-year adjusted free cash flow (FCF) was approximately $3.8B, significantly higher than the roughly $3.0B guidance provided last quarter, benefiting from stronger year-end sales volume, better product mix (selling more high-margin products), and timing factors. The year-end cash balance reached $4.9B.

  8. Major organizational restructuring announced, creating two new reporting segments to enhance specialty platform visibility: Cencora announced a reorganization of its reporting structure into two new segments: "Specialty Physician Services" and "Pharmaceutical Distribution and Services." Long-term operating income growth targets were also announced—approx. 14%–16% for the former and mid-single digits for the latter. CEO Bob Mauch stated this move integrates all specialty service assets under a single leader, helping to accelerate innovation and improve transparency for shareholders.

  9. Acquisition of majority stake in American Oncology Network announced, MSO platform continues to expand: Cencora agreed to acquire a majority stake in American Oncology Network (AON), a physician-led network with over 350 providers across 21 states, serving as a significant extension to the existing OneOncology and RCA platforms. The Management Services Organization (MSO) platform contributed approximately 10% of total corporate adjusted operating income for the full fiscal year 2026.

Sign up for free!

You can sign up for free or Log In to read more information!

Free In-Depth for popular US stocks:

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer